Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Huya, Zhejiang in pact to ramp up TCM development
Currently, Huya’s novel anti-arrhythmic compound HBI-3000 is under development in both China and the US. Huya CTO and COO China Clement Gingras said the alliance with Zhejiang Chinese
Currently, Huya’s novel anti-arrhythmic compound HBI-3000 is under development in both China and the US. Huya CTO and COO China Clement Gingras said the alliance with Zhejiang Chinese
The licensing deal covers a combination drug, using Zertane and another erectile dysfunction drug (PDE5 inhibitors and others), to simultaneously treat premature ejaculation and erectile dysfunction (ED). The
The trial aims to determine the tolerability, safety and pharmacokinetic profile of NKTR-181 upon repeat administration in preparation for Phase 2 clinical development in chronic pain patients. In
The trial aims to assess the safety and tolerability of intravenous ME-143 in patients with refractory solid tumors. The company expects to recruit around 24 patients with final
Naeymi-Rad will succeed John Campbell, who co-founded the firm more than 14 years ago. Campbell Alliance was acquired by inVentiv Health in February 2011 and operates as inVentiv
The new joint venture company – Jilin Pfizer Guoyuan Animal Health – will initially be responsible to develop vaccines to protect the health of swine. Jilin Guoyuan Animal
Under the contract, Maxwell will fund the Phase I and II human clinical studies of AHRO-001 in Russia. In return, AtheroNova will issue up to $4.1m in common
The recommendation is based on the results from a double-blind Rocket AF Phase 3 trial which showed that once-daily rivaroxaban had a 21% relative risk reduction in stroke
The aim of the trial is to compare the objective response rate (ORR) of carboplatin and paclitaxel with or without bavituximab in up to 86 patients with previously
Following the acquisition, Amira has become the wholly-owned subsidiary of BMS. Earlier in July 2011, BMS signed a definitive agreement to acquire Amira for $325m. The deal allowed